CalciMedica, Inc. filings document regulatory disclosures for a clinical-stage biopharmaceutical company developing CRAC channel inhibition therapies. The company’s Form 8-K reports cover results of operations and financial condition, clinical program events involving Auxora, and related updates for inflammatory and immunologic disease programs.
The filing record also includes capital-structure and governance disclosures, including Nasdaq continued-listing compliance matters, at-the-market offering documentation, shareholder voting matters, and the company’s common stock registration on The Nasdaq Capital Market under the symbol CALC.
CalciMedica, Inc. Chief Financial Officer Stephen Bardin received a direct grant of employee stock options covering 190,000 shares of common stock on September 24, 2026. The options have an exercise price of $1.74 per share and expire September 23, 2036. Beginning September 24, 2026, 1/48th of the shares subject to the option vest in equal monthly installments over a four-year period.
A. Rachel Leheny, CalciMedica's chief executive officer, received an award of options covering 360,000 shares on September 24, 2026, with an exercise price of $1.74 per share. The options vest in equal monthly installments of 1/48th beginning September 24, 2026, over a four-year period, and expire September 23, 2036.
CalciMedica, Inc. (CALC) reports that it has regained compliance with Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price requirement. Nasdaq’s Listing Qualifications Department notified the company on September 15, 2026 that, for 10 consecutive business days from August 31 to September 14, 2026, the closing bid price of its common stock was at or above $1.00 per share, satisfying the Minimum Bid Price Requirement. This cures the deficiency previously noted in a March 16, 2026 notice, which had given the company 180 calendar days, until September 14, 2026, to regain compliance. As of this report, CalciMedica states that it has no outstanding deficiency notices from Nasdaq.
CalciMedica, Inc. (CALC) reports an update on its Nasdaq listing status. After previously falling below Nasdaq’s $35,000,000 market value of listed securities requirement, Nasdaq has now determined that CalciMedica satisfies the alternative stockholders’ equity standard under Listing Rule 5550(b)(1), based on reported equity of $5,513,000 as of June 30, 2026. This closes the prior deficiency related to market value of listed securities.
The company remains out of compliance with Nasdaq’s $1.00 Minimum Bid Price Requirement under Listing Rule 5550(a)(2). CalciMedica has until September 14, 2026 to regain compliance. A one-for-five reverse stock split of its common stock became effective at 5:00 p.m. Eastern Time on August 28, 2026, but there is no assurance the company will meet the minimum bid price or maintain overall listing compliance.
CalciMedica, Inc. (CALC) approved and is implementing a 1-for-5 reverse stock split of its outstanding common stock and a reduction of authorized common shares from 500,000,000 to 100,000,000 through a Certificate of Amendment filed in Delaware.
The amendment becomes effective at 5:00 p.m. Eastern Time on August 28, 2026. Every five issued and outstanding common shares will be combined into one share, with no change in par value. Equity awards, warrants and plan reserves will be adjusted proportionately, and holders otherwise entitled to fractional shares will receive cash instead. CALC shares will begin trading on a split-adjusted basis on August 31, 2026 on The Nasdaq Capital Market under the same ticker.
CalciMedica, Inc. (CALC) has a significant shareholder group led by Stonepine Capital Management, LLC reporting ownership on a Schedule 13G. Stonepine Capital Management, Stonepine Capital, L.P., Stonepine GP, LLC, and Jon M. Plexico together report beneficial ownership of 2,149,522 CalciMedica common stock equivalents, representing 6.0% of the outstanding common stock.
The position consists of 643,357 shares of common stock and warrants to acquire an additional 1,506,165 shares, all subject to a 9.99% beneficial ownership limitation. The ownership percentage is based on 34,141,460 shares of common stock outstanding as of August 5, 2026. Voting and dispositive powers over these securities are reported as shared among the Stonepine entities and Plexico, with no sole voting or dispositive power.
CalciMedica, Inc. (CALC) reported that major stockholder ALAFI CAPITAL CO LLC acquired two new warrant positions on August 19, 2026. The holder received 3,529,192 Series A Warrants exercisable into the same number of common shares at $0.8033 per share and 3,529,192 Series B Warrants at an exercise price of $1.00 per share. The Series A Warrants expire on the earlier of 18 months after the closing date of a related private placement or 30 days following CalciMedica’s public announcement of FDA clearance of its Investigational New Drug Application for CM5480, while the Series B Warrants expire on June 23, 2031. After these transactions, ALAFI CAPITAL CO LLC directly holds 5,112,345 shares of CalciMedica common stock.
CalciMedica, Inc. (CALC) received an updated Schedule 13D from Alafi Capital Company LLC and Christopher D. Alafi reporting their beneficial ownership of 7,220,101 shares of common stock and related warrants, representing 19.9% of the class based on 34,141,460 shares outstanding as of August 20, 2026.
The position includes 5,112,345 common shares plus multiple warrant series. On August 19, 2026, after Stockholder Approval, the reporting persons received 3,529,192 Series A Warrants and 3,529,192 Series B Warrants. Due to a 19.99% beneficial ownership limitation, 2,605,965 Series A Warrants and 2,605,965 Series B Warrants are not currently exercisable. The filing states the amendment’s purpose is solely to reflect this warrant issuance, with no stated change in transaction purpose.
CalciMedica, Inc. (CALC) reported that director Allan Shaw received a grant of 10,000 Director Stock Options to purchase common stock. The options have an exercise price of $0.6131 per share and expire on August 18, 2036. According to the vesting terms, 1/12 of the shares vest in equal monthly installments over one year following the grant date, and the award will in any case be fully vested on the date of CalciMedica’s 2027 annual meeting of stockholders. Following this grant, Shaw holds 10,000 options directly.
CalciMedica, Inc. (CALC) reported that director Alan Glicklich received a grant of 10,000 Director Stock Options to purchase Common Stock at an exercise price of $0.6131 per share. The options expire on August 18, 2036 and are scheduled to vest monthly over one year, and in any event be fully vested by the 2027 annual meeting of stockholders.